SCHEMBL4482182

SCHEMBL4482182

O=C1Nc2cc(Cl)ccc2C1=C(Nc1ccc(F)cc1)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.50
KDR P35968 5/20 0.47
CES1 P23141 1/20 0.42
RXFP1 Q9HBX9 2/20 0.41
MAPT P10636 2/20 0.41
TP53 P04637 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
P2RX1 P51575 1/20 0.41
FLT3 P36888 2/20 0.39
AURKA O14965 1/20 0.39
PDGFRB P09619 1/20 0.39
PDGFRA P16234 1/20 0.39
AURKB Q96GD4 1/20 0.39
AURKC Q9UQB9 1/20 0.39
GRIK1 P39086 1/20 0.39
TUBB4A P04350 1/20 0.39
TUBB P07437 1/20 0.39
TUBA3C P0DPH7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4482176 1.00 BACE1 (0.50) BACE1KDRCES1RXFP1MAPT
SCHEMBL4507721 0.93 CES1 (0.46) BACE1KDRCES1RXFP1MAPT
SCHEMBL4507715 0.93 CES1 (0.46) BACE1KDRCES1RXFP1MAPT
SCHEMBL4496719 0.92 CES1 (0.47) BACE1KDRCES1RXFP1MAPT
SCHEMBL4496723 0.92 CES1 (0.47) BACE1KDRCES1RXFP1MAPT
SCHEMBL4500246 0.90 CES1 (0.43) BACE1KDRCES1RXFP1TP53
SCHEMBL4500243 0.90 CES1 (0.43) BACE1KDRCES1RXFP1TP53
SCHEMBL4493857 0.89 PLK1 (0.46) BACE1KDRCES1RXFP1FLT3
SCHEMBL4478326 0.89 CES1 (0.42) BACE1KDRCES1RXFP1FLT3
SCHEMBL4478322 0.89 CES1 (0.42) BACE1KDRCES1RXFP1FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514468-B2 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-04-07 US disclosed
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions KDR, FLT1, EGFR BACE1 1615/4885KDR 1/4885CES1 2176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.